Advanced search×
×
  1. Angiosarcoma de mama tras tratamiento conservador en cáncer de mama

    Medicina Clínica 124(13):515 (2005) PMID 15847772

  2. [Angiosarcoma in an irradiated breast: a case description].

    Actas Dermo-Sifiliográficas 96(9):602 (2005) PMID 16476306

    We present a case of cutaneous angiosarcoma of the breast, diagnosed 6 years after a carcinoma of the breast had been treated with radiation. The patient was a 44-year-old female with a history of ductal carcinoma (CA) of the right breast treated with tumorectomy, axillary lymphadenectomy, chemother...
  3. Neoadjuvant therapy of early stage human epidermal growth factor receptor 2 positive breast cancer: latest evidence and clinical implication...

    Therapeutic Advances in Medical Oncology 6(5):210 (2014) PMID 25342988 PMCID PMC4206611

    Neoadjuvant therapy in human epidermal growth factor receptor 2 (HER2)-positive breast cancer is exactly the paradigm of targeted therapy and a suitable setting to develop and test rapidly novel therapies in early stages. Moreover, neoadjuvant approaches provide a significant source of tumour tissue...
  4. Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clin...

    Breast Cancer Research and Treatment 134(3):1161 (2012) PMID 22772380

    We conducted a prospectively monitorized series of consecutive patients with early or locally advanced Her-2 positive breast cancer following the same treatment strategy. Stage II-IIIC HER2-positive breast cancer patients, including inflammatory disease, were treated with weekly-trastuzumab for 24 w...
  5. Avoiding axillary treatment in sentinel lymph node micrometastases of breast cancer: a prospective analysis of axillary or distant recurrenc...

    Annals of Surgical Oncology 17(3):772 (2010) PMID 20183912

    The need for axillary lymph node dissection (ALND) in breast cancer patients with sentinel lymph node (SLN) micrometastases remains controversial. The aims of the study were to evaluate the locoregional failure and outcome of breast cancer patients with sentinel node micrometastases who did not unde...
  6. Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin.

    Oncotarget 4(9):1484 (2013) PMID 23986086 PMCID PMC3824528

    We used the clonal breast cancer cell line MCF10DCIS.com, which harbors the gain-of-function H1047R hot-spot mutation in the catalytic domain of the PI3KCA gene and has been shown to form DR-refractory xenotumors. To model PIK3CA-activating mutations in late stages of cancer, we took advantage of th...
  7. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.

    Current Medical Research and Opinion 25(10):2533 (2009) PMID 19722781

    Febrile neutropenia (FN) is associated with disruption of planned chemotherapy and increased management costs. However, the economic impact of FN in Spanish clinical practice has not been documented hitherto. A multicenter, retrospective chart review of adults with breast or lung cancer or non-Hodgk...
  8. Avoiding Axillary Treatment in Sentinel Lymph Node Micrometastases of Breast Cancer: A Prospective Analysis of Axillary or Distant Recurrenc...

    Annals of Surgical Oncology 17(3):772 (2010) PMID 19915920

    Breast cancer patients with SLN micrometastases in whom ALND was omitted had a very low locoregional failure rate. This study supports the theory that ALND might be avoided in these patients, providing that adjuvant systemic treatment equal to treatment provided to treat node-positive disease is adm...